The high resolution chest scan is the gold standard for the screening of interstitial lung disease, but this remains an onerous examination, and irradiating.

Ultrasound could be used to detect these disorders with a very good sensitivity and specificity. This exam offers the advantage of being non radiating, inexpensive, and accessible to the rheumatologist who already uses it in their daily practice.

The investigators want to assess the lung ultrasound performance compared with the gold standard.

Patients will be included during a regular follow-up consultation with their referent rheumatologist. If there is an indication of first line biotherapy or targeted therapy the doctor will propose to the patient to participate in the study, give him the information leaflet, collect orally non-opposition, and will complete a survey for evaluation of the general health and potential risk factors for interstitial lung.

Inclusion Criteria:

• Men and women over the age of 18
• With rheumatoid arthritis meeting the criteria ACR (American College of Rheumatology)/ EULAR (EUropean League Against Rheumatism) 2010
• Never received any biotherapy or targeted therapy
• Having an indication of introduction of biotherapy or therapy targeted (JAK inhibitors) (JAK : Janus kinase)

Exclusion Criteria:

• Refusal to participate in the study
• Known pulmonary disease that can alter lung interstitium: cardiac decompensation, COPD (chronic obstructive pulmonary disease), thoracic surgery, infection pulmonary
• Patient with respiratory functional signs suggestive of PID (Diffuse interstitial lung disease)
• Patient with signs of cardiac decompensation
• Patient with pulmonary auscultation suggestive of PID
• Pregnant or lactating woman
• Psychiatric pathology seriously hindering understanding
• Difficulty understanding oral French
• Person deprived of liberty or under legal protection

Patients followed for a rheumatoid arthritis